Personalizing antiplatelet therapy with clopidogrel

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 476-485

  Trenk, D ^a   Zolk, O ^b   Fromm, M F ^b   Neumann, F J ^a   Hochholzer, W ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL; TICAGRELOR; TICLOPIDINE;

ALLELE; ARTICLE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOADING DRUG DOSE; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

BLOOD PLATELETS; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84866618180     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.133     Document Type: Article

References (78)

1. Schömig, A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334, 1084-1089 (1996).
2. Bertrand, M.E., Rupprecht, H.J., Urban, P. & Gershlick, A.H.; cLASSIcS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (cLASSIcS). Circulation 102, 624-629 (2000).
3. Sabatine, M.S. et al. Addition of clopidogrel to aspirin and fbrinolytic therapy for myocardial infarction with St-segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005).
4. The clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events trial Investigators. Efects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without St-segment elevation. N Engl J Med. 345, 494-502 (2001).
5. Smith, S.c. Jr et al. Acc/AHA/ScAI 2005 guideline update for percutaneous coronary intervention: a report of the American college of cardiology/American Heart Association task Force on Practice Guidelines (Acc/AHA/ScAI Writing committee to Update the 2001 Guidelines for Percutaneous coronary Intervention). J. Am. Coll. Cardiol. 47, e1-121 (2006).
6. Anderson, J.L., et al. Acc/AHA 2007 guidelines for the management of patients with unstable angina/non-St-Elevation myocardial infarction: a report of the American college of cardiology/American Heart Association task Force on Practice Guidelines (Writing committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-St-Elevation Myocardial Infarction) developed in collaboration with the American college of Emergency Physicians, the Society for cardiovascular Angiography and Interventions, and the Society of thoracic Surgeons endorsed by the American Association of cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 50, e1-e157 (2007).
7. Bonello, L. et al. consensus and future directions on the defnition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919-933 (2010).
8. Hochholzer, W. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48, 1742-1750 (2006).
9. Trenk, D. et al. cytochrome P450 2c19 681GA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51, 1925-1934 (2008).
10. Sibbing, D. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53, 849-856 (2009).
11. Sibbing, D. et al. cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512-518 (2010).
12. Hochholzer, W. et al. Impact of cytochrome P450 2c19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55, 2427-2434 (2010).
13. Savi, P. et al. Identifcation and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891-896 (2000).
14. Steinhubl, S.R. et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103, 2572-2578 (2001).
15. Gurbel, P.A., Bliden, K.P., Hiatt, B.L. & O'connor, C.M. clopidogrel for coronary stenting: response variability, drug resistance, and the efect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003).
16. Breet, N.J. et al. comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754-762 (2010).
17. Aradi, D. et al. Prognostic signifcance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am. Heart J. 160, 543-551 (2010).
18. Brar, S.S. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J. Am. Coll. Cardiol. 58, 1945-1954 (2011).
19. Montalescot, G. et al. A randomized comparison of high clopidogrel loading doses in patients with non-St-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of clopidogrel to Blunt Platelet Activation, Infammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48, 931-938 (2006).
20. von Beckerath, N., Taubert, D., Pogatsa-Murray, G., Schömig, E., Kastrati, A. & Schömig, A. Absorption, metabolization, and antiplatelet efects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-cHOIcE (Intracoronary Stenting and Antithrombotic Regimen: choose Between 3 High Oral Doses for Immediate clopidogrel Efect) trial. Circulation 112, 2946-2950 (2005).
21. Hochholzer, W. et al. time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111, 2560-2564 (2005).
22. Bonello, L. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008).
23. Angiolillo, D.J. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet therapy in Diabetes Mellitus (OPtIMUS) study. Circulation 115, 708-716 (2007).
24. Trenk, D. et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufcient platelet inhibition after clopidogrel loading for elective coronary stent placement. EuroIntervention 4, 214-221 (2008).
25. von Beckerath, N. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J. 28, 1814-1819 (2007).
26. Wiviott, S.D. et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in comparison to clopidogrel for Inhibition of Platelet Activation and Aggregation-thrombolysis in Myocardial Infarction 44 trial. Circulation 116, 2923-2932 (2007).
27. Payne, C.D., et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 19, 275-281 (2008).
28. Angiolillo, D.J. et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J. Am. Coll. Cardiol. 56, 1017-1023 (2010).
29. Gurbel, P.A. et al. Response to ticagrelor in clopidogrel nonresponders and responders and efect of switching therapies: the RESPOND study. Circulation 121, 1188-1199 (2010).
30. Jeong, Y.H. et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the AccEL-RESIStANcE (Adjunctive cilostazol Versus High Maintenance Dose clopidogrel in Patients With clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53, 1101-1109 (2009).
31. Cuisset, t. et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC. Cardiovasc. Interv. 1, 649-653 (2008).
32. Wiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
33. Wallentin, L. et al. ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
34. Mehta, S.R. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363, 930-942 (2010).
35. Parodi, G. et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PcI. JAMA 306, 1215-1223 (2011).
36. Price, M.J. et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVItAS randomized trial. JAMA 305, 1097-1105 (2011).
37. Trenk, D. et al. A Randomized trial of Prasugrel Versus clopidogrel in Patients With High Platelet Reactivity on clopidogrel After Elective Percutaneous coronary Intervention With Implantation of Drug-Eluting Stents: Results of the tRIGGER-PcI (testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on clopidogrel to Guide Alternative therapy With Prasugrel) Study. J. Am. Coll. Cardiol. 59, 2159-2164 (2012).
38. Taubert, D. et al. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 80, 486-501 (2006).
39. Simon, t. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
40. Mega, J.L. et al. Genetic variants in ABcB1 and cYP2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the tRItON-tIMI 38 trial: a pharmacogenetic analysis. Lancet 376, 1312-1319 (2010).
41. Trenk, D., Hochholzer, W., Fromm, M.F., Kleyer, A., Pahl, A., Neumann, F.-J. Polymorphism of MDR-1 and the organic anion-transporting polypeptide (OAtP) 1B1 have no impact on antiplatelet efect of a 600-mg loading dose of clopidogrel in patients undergoing PcI. Eur Heart J 29 (suppl.), 832 Abstract P4781 (2008).
42. Shuldiner, A.R. et al. Association of cytochrome P450 2c19 genotype with the antiplatelet efect and clinical efcacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
43. Wallentin, L. et al. Efect of cYP2c19 and ABcB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLAtO trial. Lancet 376, 1320-1328 (2010).
44. Luo, M., Li, J., Xu, X., Sun, X. & Sheng, W. ABcB1 c3435t polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb. Res. 129, 754-759 (2012).
45. clarke, t.A. & Waskell, L.A. the metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31, 53-59 (2003).
46. Kurihara, A., Hagihara, K., Kazui, M., Ozeki, t., Farid, N.A. & Ikeda, t. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev. 37, 99 (2005).
47. Hulot, J.S. et al. cytochrome P450 2c19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
48. Scott, S.A. et al. clinical Pharmacogenetics Implementation consortium guidelines for cytochrome P450-2c19 (cYP2c19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011).
49. Giusti, B. et al. cytochrome P450 2c19 loss-of-function polymorphism, but not cYP3A4 IVS10 + 12G/A and P2Y12 t744c polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17, 1057-1064 (2007).
50. Geisler, t. et al. cYP2c19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9, 1251-1259 (2008).
51. Collet, J.P. et al. cytochrome P450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
52. Mega, J.L. et al. cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
53. Mega, J.L. et al. Reduced-function cYP2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PcI: a meta-analysis. JAMA 304, 1821-1830 (2010).
54. US Food and Drug Administration. FDA Drug Safety communication: reduced efectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888htm. Accessed 3 December 2010.
55. Sibbing, D. et al. Isolated and interactive impact of common cYP2c19 genetic variants on the antiplatelet efect of chronic clopidogrel therapy. J. Thromb. Haemost. 8, 1685-1693 (2010).
56. Frére, C., Cuisset, t., Gaborit, B., Alessi, M.c. & Hulot, J.S. the cYP2c19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-St acute coronary syndrome. J. Thromb. Haemost. 7, 1409-1411 (2009).
57. Tantry, U.S. et al. First analysis of the relation between cYP2c19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSEt/OFFSEt and RESPOND genotype studies. Circ. Cardiovasc. Genet. 3, 556-566 (2010).
58. Blatter, M.C., James, R.W., Messmer, S., Barja, F. & Pometta, D. Identifcation of a distinct human high-density lipoprotein subspecies defned by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211, 871-879 (1993).
59. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efcacy. Nat. Med. 17, 110-116 (2011).
60. Fontana, P. et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J. Thromb. Haemost. 9, 1664-1666 (2011).
61. Lewis, J.P. et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin. Pharmacol. Ther. 90, 568-574 (2011).
62. Rideg O., et al. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 12, 1269-1280 (2011).
63. Sibbing, D. et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur. Heart J. 32, 1605-1613 (2011).
64. Simon, t. et al. Efect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin. Pharmacol. Ther. 90, 561-567 (2011).
65. Trenk, D. et al. Paraoxonase-1 Q192R polymorphism and antiplatelet efects of clopidogrel in patients undergoing elective coronary stent placement. Circ. Cardiovasc. Genet. 4, 429-436 (2011).
66. Dansette, P.M., Rosi, J., Bertho, G. & Mansuy, D. Paraoxonase-1 and clopidogrel efcacy. Nat. Med. 17, 1040-1; author reply 1042 (2011).
67. Roberts, J.D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379, 1705-1711 (2012).
68. Gladding, P. et al. the pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINc (Plavix Response in coronary Intervention) trial. JACC. Cardiovasc. Interv. 1, 620-627 (2008).
69. Bonello, L. et al. clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2c19*2 loss of function polymorphism. J. Am. Coll. Cardiol. 56, 1630-1636 (2010).
70. Collet, J.P. et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover cLOVIS-2 (clopidogrel and Response Variability Investigation Study 2). JACC. Cardiovasc. Interv. 4, 392-402 (2011).
71. Mega, J.L. et al. Dosing clopidogrel based on cYP2c19 genotype and the efect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221-2228 (2011).
72. Bates, E.R., Lau, W.c. & Angiolillo, D.J. clopidogrel-drug interactions. J. Am. Coll. Cardiol. 57, 1251-1263 (2011).
73. Bhatt, D.L. et al. clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363, 1909-1917 (2010).
74. Rehmel, J.L. et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab. Dispos. 34, 600-607 (2006).
75. Brandt, J.t. et al. common polymorphisms of cYP2c19 and cYP2c9 afect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
76. Mega, J.L. et al. cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
77. Geisler, t. et al. the Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDIct) score. J. Thromb. Haemost. 6, 54-61 (2008).
78. Sangkuhl, K., Klein, t.E. & Altman, R.B. clopidogrel pathway. Pharmacogenet. Genomics 20, 463-465 (2010).